biostudies-literatureSahm KDeutsche ForschungsgemeinschaftGemeinnützige Hertie-StiftungElse Kröner-Fresenius-Stiftung (Else Kroner-Fresenius Foundation)Deutsche Forschungsgemeinschaft (German Research Foundation)Gemeinnützige Hertie-Stiftung (Hertie Foundation)Else Kröner-Fresenius-Stiftung186https://www.ebi.ac.uk/biostudies/studies/S-EPMC10728097biostudies-literatureUnknown3(1)<h4>Background</h4>Concurrent malignant brain tumors in patients with multiple sclerosis (MS) constitute a rare but paradigmatic phenomenon for studying neuroimmunological mechanisms from both molecular and clinical perspectives.<h4>Methods</h4>A multicenter cohort of 26 patients diagnosed with both primary brain tumors and multiple sclerosis was studied for disease localization, tumor treatment-related MS activity, and molecular characteristics specific for diffuse glioma in MS patients.<h4>Results</h4>MS neither predisposes nor protects from the development of gliomas. Patients with glioblastoma WHO grade 4 without isocitratdehydrogenase (IDH) mutations have a longstanding history of MS, whereas patients diagnosed with IDH-mutant astrocytoma WHO grade 2 receive multiple sclerosis diagnosCommunications medicineConcurrent gliomas in patients with multiple sclerosis.PMC107280972019_EKMS.2339404578P1200013Eisele PBendszus MMildenberger IHerold-Mende Cvon Deimling ASeliger CKonig LZeiner PSMeuth SGCapper DSperk ESchrimpf DSahm FSahm KTabatabai GPlatten MWick WBreckwoldt MORatliff MKessler TfalseConcurrent gliomas in patients with multiple sclerosis.<h4>Background</h4>Concurrent malignant brain tumors in patients with multiple sclerosis (MS) constitute a rare but paradigmatic phenomenon for studying neuroimmunological mechanisms from both molecular and clinical perspectives.<h4>Methods</h4>A multicenter cohort of 26 patients diagnosed with both primary brain tumors and multiple sclerosis was studied for disease localization, tumor treatment-related MS activity, and molecular characteristics specific for diffuse glioma in MS patients.<h4>Results</h4>MS neither predisposes nor protects from the development of gliomas. Patients with glioblastoma WHO grade 4 without isocitratdehydrogenase (IDH) mutations have a longstanding history of MS, whereas patients diagnosed with IDH-mutant astrocytoma WHO grade 2 receive multiple sclerosis diagnos2023-01-01T00:00:00Z2023 Dec2026-07-14T22:42:51.951Z2026-06-26T03:07:05.686ZS-EPMC107280973811062610.1038/s43856-023-00381-y